New cancer drug enters first human trials for advanced solid tumors
NCT ID NCT06265688
Summary
This is the first study in humans testing a new cancer drug called CX-2051. Researchers want to find the safest dose and see if it helps control advanced solid tumors, either by itself or combined with another cancer drug (bevacizumab). The study will enroll about 160 adults whose cancer has progressed after standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Carolina BioOncology Institute, PLLC
RECRUITINGHuntersville, North Carolina, 28078, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Sarah Cannon Research Institute at HealthONE
RECRUITINGDenver, Colorado, 80218, United States
-
Sarah Cannon Research Institute, LLC
RECRUITINGNashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.